Read More:
Distribution
Viking Therapeutics Inc. (VKNG) saw a surge in its stock price following the release of positive results from its Phase 1 clinical trial for its oral obesity drug.
Promising Results
The data from the trial showed promising results, with the drug demonstrating efficacy and safety in treating obesity in both male and female patients.
Market Reaction
Investors reacted positively to the news, driving Viking Therapeutics stock up by more than 20% in after-hours trading.
Future Prospects
This success in the Phase 1 trial bodes well for the future of Viking Therapeutics and its potential in the obesity treatment market.
Conclusion
With this significant milestone achieved, Viking Therapeutics is well-positioned to continue its research and development efforts for its oral obesity drug.
Read More:
- Sweeping public safety bill in D.C. aims to increase security, undoing past changes
- Get Ready for Enchanting Adventures in Season 4 with Witch Doctor
- Talk therapy shown to be effective in addressing psychological factors contributing to back pain
- Microsoft eliminates Android app integration on Windows 11
- Seven Years Later: Racing Game Enjoys Explosive Success on Steam Thanks to Epic Sale
+ There are no comments
Add yours